Panaccione, RemoColombel, Jean-FredericTravis, Simon P. L.Bossuyt, PeterBaert, FilipVanasek, TomasDanalioglu, Ahmet2020-10-222020-10-22Panaccione R., Colombel J., Travis S. P. L. , Bossuyt P., Baert F., Vanasek T., Danalioglu A., Novacek G., Armuzzi A., Reinisch W., et al., -Tight control for Crohn-s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial-, GUT, cilt.69, ss.658-664, 2020http://hdl.handle.net/20.500.12645/24070https://gut.bmj.com/content/69/4/658.longObjective To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn-s disease (CD) naive to immunosuppressants and biologics using a UK public payer perspective.info:eu-repo/semantics/openAccessCrohn-s diseaseArticleWOS:0005211119000078506856008510.1136/gutjnl-2019-31825631285357